We recently conducted a monocentric study, termed EMULATING (EGFR MUtation status from pLAsma: circulaTING tumor DNA analysis in NSCLC patients), which investigated the ability to detect in plasma of advanced NSCLC patients EGFR mutations previously identified in matched tumor tissue biopsy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.